Multiple infliximab biosimilar switches: Results following a nationwide switch from originator infliximab to biosimilar CT-P13, and subsequently to biosimilar GP1111, in real-world patients with inflammatory arthritis followed in the Danish DANBIO registry

Hafsah Nabi; Bente Glintborg; AG Loft; O Hendricks; JK Pedersen; SA Just; Rabiah Ahmed; Kamilla  Danebod; HL Munk; A Colic; A Linauskas; Dorte Vendelbo Jensen; LB Christensen; Natalia Manilo; N Lomborg; S Kristensen; F Mehnert; NS Krogh; Merete Lund Hetland

Multiple infliximab biosimilar switches: Results following a nationwide switch from originator infliximab to biosimilar CT-P13, and subsequently to biosimilar GP1111, in real-world patients with inflammatory arthritis followed in the Danish DANBIO registry

Hafsah Nabi, Bente Glintborg, AG Loft, O Hendricks, JK Pedersen, SA Just, Rabiah Ahmed, Kamilla Danebod, HL Munk, A Colic, A Linauskas, Dorte Vendelbo Jensen, LB Christensen, Natalia Manilo, N Lomborg, S Kristensen, F Mehnert, NS Krogh, Merete Lund Hetland

Afdeling for Rygkirurgi, Led- og Bindevævssygdomme

Originalsprog	Engelsk
Artikelnummer	OP16
Bogserie	Scandinavian Journal of Rheumatology, Supplement
Vol/bind	50
Udgave nummer	130
Sider (fra-til)	14-5
Antal sider	2
ISSN	0301-3847
Status	Udgivet - 2021

Citationsformater

Nabi, H., Glintborg, B., Loft, AG., Hendricks, O., Pedersen, JK., Just, SA., Ahmed, R., Danebod, K., Munk, HL., Colic, A., Linauskas, A., Jensen, D. V., Christensen, LB., Manilo, N., Lomborg, N., Kristensen, S., Mehnert, F., Krogh, NS., & Hetland, M. L. (2021). Multiple infliximab biosimilar switches: Results following a nationwide switch from originator infliximab to biosimilar CT-P13, and subsequently to biosimilar GP1111, in real-world patients with inflammatory arthritis followed in the Danish DANBIO registry. Scandinavian Journal of Rheumatology, Supplement, 50(130), 14-5. Artikel OP16.

Multiple infliximab biosimilar switches: Results following a nationwide switch from originator infliximab to biosimilar CT-P13, and subsequently to biosimilar GP1111, in real-world patients with inflammatory arthritis followed in the Danish DANBIO registry. / Nabi, Hafsah ; Glintborg, Bente; Loft, AG et al.
I: Scandinavian Journal of Rheumatology, Supplement, Bind 50, Nr. 130, OP16, 2021, s. 14-5.

Publikation: Bidrag til tidsskrift › Konferenceabstrakt i tidsskrift › Forskning › peer review

Nabi, H , Glintborg, B, Loft, AG, Hendricks, O, Pedersen, JK, Just, SA, Ahmed, R, Danebod, K, Munk, HL, Colic, A, Linauskas, A, Jensen, DV, Christensen, LB, Manilo, N, Lomborg, N, Kristensen, S, Mehnert, F, Krogh, NS & Hetland, ML 2021, 'Multiple infliximab biosimilar switches: Results following a nationwide switch from originator infliximab to biosimilar CT-P13, and subsequently to biosimilar GP1111, in real-world patients with inflammatory arthritis followed in the Danish DANBIO registry', Scandinavian Journal of Rheumatology, Supplement, bind 50, nr. 130, OP16, s. 14-5.

Nabi H , Glintborg B, Loft AG, Hendricks O, Pedersen JK, Just SA et al. Multiple infliximab biosimilar switches: Results following a nationwide switch from originator infliximab to biosimilar CT-P13, and subsequently to biosimilar GP1111, in real-world patients with inflammatory arthritis followed in the Danish DANBIO registry. Scandinavian Journal of Rheumatology, Supplement. 2021;50(130):14-5. OP16.

Nabi, Hafsah ; Glintborg, Bente ; Loft, AG et al. / Multiple infliximab biosimilar switches: Results following a nationwide switch from originator infliximab to biosimilar CT-P13, and subsequently to biosimilar GP1111, in real-world patients with inflammatory arthritis followed in the Danish DANBIO registry. I: Scandinavian Journal of Rheumatology, Supplement. 2021 ; Bind 50, Nr. 130. s. 14-5.

@article{109ecceb157041dc81755f0822248cab,

title = "Multiple infliximab biosimilar switches: Results following a nationwide switch from originator infliximab to biosimilar CT-P13, and subsequently to biosimilar GP1111, in real-world patients with inflammatory arthritis followed in the Danish DANBIO registry",

author = "Hafsah Nabi and Bente Glintborg and AG Loft and O Hendricks and JK Pedersen and SA Just and Rabiah Ahmed and Kamilla Danebod and HL Munk and A Colic and A Linauskas and Jensen, {Dorte Vendelbo} and LB Christensen and Natalia Manilo and N Lomborg and S Kristensen and F Mehnert and NS Krogh and Hetland, {Merete Lund}",

note = "COPECARE",

year = "2021",

language = "English",

volume = "50",

pages = "14--5",

journal = "Scandinavian Journal of Rheumatology, Supplement",

issn = "0301-3847",

publisher = "Taylor & Francis A B",

number = "130",

}

TY - ABST

T1 - Multiple infliximab biosimilar switches: Results following a nationwide switch from originator infliximab to biosimilar CT-P13, and subsequently to biosimilar GP1111, in real-world patients with inflammatory arthritis followed in the Danish DANBIO registry

AU - Nabi, Hafsah

AU - Glintborg, Bente

AU - Loft, AG

AU - Hendricks, O

AU - Pedersen, JK

AU - Just, SA

AU - Ahmed, Rabiah

AU - Danebod, Kamilla

AU - Munk, HL

AU - Colic, A

AU - Linauskas, A

AU - Jensen, Dorte Vendelbo

AU - Christensen, LB

AU - Manilo, Natalia

AU - Lomborg, N

AU - Kristensen, S

AU - Mehnert, F

AU - Krogh, NS

AU - Hetland, Merete Lund

N1 - COPECARE

PY - 2021

Y1 - 2021

M3 - Conference abstract in journal

SN - 0301-3847

VL - 50

SP - 14

EP - 15

JO - Scandinavian Journal of Rheumatology, Supplement

JF - Scandinavian Journal of Rheumatology, Supplement

IS - 130

M1 - OP16

ER -